Drug Resistance in Leukemia and Lymphoma III Book

1	MDR 1/P-gp Expression as a Prognostic Factor in Acute Leukemias	1
2	Clinical Significance of P-Glycoprotein (P-gp) Expression in Childhood Acute Lymphoblastic Leukemia: Results of a 6-Year Prospective Study	11
3	Prognostic Value of P-gp Expression and Related Function in Childhood Acute Leukemia	21
4	Comparison of P-Glycoprotein Expression and Function with in Vitro Sensitivity to Anthracyclines in AML	29
5	Quinine Improves Results of Intensive Chemotherapy (IC) in Myelodysplastic Syndromes (MDS) Expressing P-Glycoprotein (PGP): Updated Results of a Randomized Study	35
6	Treatment of Poor Prognosis AML Patients Using PSC833 (Valspodar) plus Mitoxantrone, Etoposide, and Cytarabine (PSC-MEC)	47
7	Assessment of P-Glycoprotein Expression by Immunocytochemistry and Flow Cytometry Using Two Different Monoclonal Antibodies Coupled with Functional Efflux Analysis in 34 Patients with Acute Myeloid Leukemia	57
8	Preliminary Immunocytochemical Studies of MDR-1 and MDR-3 Pgp Expression in B-Cell Leukemias	65
9	A Mutation in the Promoter of the Multidrug Resistance Gene (MDR1) in Human Hematological Malignancies May Contribute to the Pathogenesis of Resistant Disease	71
10	Reproducible Flow Cytometric Methodology for Measuring Multidrug Resistance in Leukaemic Blasts	77
11	Natural Fluorescence Imaging of Leukemic Cells for Studying Uptake and Retention of Anthracyclines	89
12	Artificial Neural Networks as Versatile Tools for Prediction of MDR-Modulatory Activity	95
13	Discordance of P-Glycoprotein Expression and Function in Acute Leukemia	107
14	Multidrug Resistance Related Proteins in Primary Cutaneous Lymphomas	119
15	The Lung Resistance Protein (LRP) Predicts Poor Outcome in Acute Myeloid Leukemia	133
16	MRP Expression in Acute Myeloid Leukemia: An Update	141
17	Evidence for Functional Discrimination between Leukemic Cells Overexpressing Multidrug-Resistance Associated Protein and P-Glycoprotein	151
18	Both Pgp and MRP1 Activities Using Calcein-AM Contribute to Drug Resistance in AML	161
19	Absolute Levels of MDR-1, MRP, and BCL-2 mRNA and Tumor Remission in Acute Leukemia	177
20	Multidrug Resistance Protein MRP1, Glutathione, and Related Enzymes: Their Importance in Acute Myeloid Leukemia	187
21	Glutathione and the Regulation of Cell Death	199
22	Evidence for the Involvement of the Glutathione Pathway in Drug Resistance in AML	205
23	Glutathione in Childhood Acute Leukemias	211
24	Apoptosis: Molecules and Mechanisms	217
25	Activation of Apoptosis Pathways by Anticancer Drugs	237
26	BCL-2 Stimulates Apoptin-Induced Apoptosis	245
27	CD95 (Fas/Apo-1) Antigen Is a New Prognostic Marker of Blast Cells of Acute Lymphoblastic Leukemia Patients	251
28	Inhibition of Fas/Fas-Ligand Does Not Block Chemotherapy-Induced Apoptosis in Drug Sensitive and Resistant Cells	259
29	Effects of PARP Inhibition on Drug and FAS-Induced Apoptosis in Leukaemic Cells	267
30	Apoptotic Fraction in Childhood ALL Assessed by DNA in Situ Labelling Is Ploidy Independent	281
31	PCNA Bearing Structures Are Retained in Apoptotic Phase of Childhood ALL Cell Cycle	289
32	Apoptosis Corrected Proliferation Fraction in Childhood ALL Is Related to Karyotype	297
33	Proliferation and Apoptosis Does Not Affect Presenting White Cell Count in Childhood ALL	305
34	Apoptosis by Anthracyclines at Therapeutic Concentrations in MDR1+ Human Leukemic Cells	313
35	BCL-2 Expression in Childhood Leukemia versus Spontaneous Apoptosis, Drug Induced Apoptosis and in Vitro Drug Resistance	325
36	Comparison of BCL-2 and Bax Protein Expression with in Vitro Sensitivity to Ara-C and 6TG in AML	335
37	Synthetic Cyclin Dependent Kinase Inhibitors: New Generation of Potent Anti-Cancer Drugs	341
38	Factors Contributing to the Resistance to Apoptosis Induced by Topoisomerase I Inhibitors in Vincristine Resistant Cells	355
39	Two Distinct Modes of Oncoprotein Expression during Apoptosis Resistance in Vincristine and Daunorubicin Multidrug-Resistant HL60 Cells	365
40	Genetic Abnormalities and Drug Resistance in Acute Lymphoblastic Leukemia	383
41	Resistance Testing and Mechanisms of Resistance in Childhood Leukemia: Studies from Amsterdam	391
42	Pharmacokinetics of Anticancer Drugs in Vitro	397
43	Down Syndrome and Acute Myeloid Leukemia: Lessons Learned from Experience with High-Dose Ara-C Containing Regimens	409
44	Cellular Drug Resistance in Childhood Acute Myeloid Leukemia: A Mini-Review with Emphasis on Cell Culture Assays	415
45	Is in Vitro Sensitivity of Blast-Cells Correlated to Therapeutic Effect in Childhood Acute Lymphoblastic Leukemia?	423
46	In Vitro Cytotoxic Drug Activity and in Vivo Pharmacokinetics in Childhood Acute Myeloid Leukemia	429
47	Prognosis in Adult AML Is Precisely Predicted by the Disc-Assay Using the Chemosensitivity-Index C[subscript 1]	437
48	Drug Resistance Testing of Acute Myeloid Leukemia in Adults Using the MTT Assay	445
49	MTT Assay for Drug Resistance in Childhood Acute Leukemia and Effect of Cyclosporin and Interferon: A Preliminary Report	453
50	Differential Antileukemic Activity of Prednisolone and Dexamethasone in Freshly Isolated Leukemic Cells	459
51	Activity of Vinorelbine on B-Chronic Lymphocytic Leukemia Cells in Vitro	473
52	Studies of Some Mechanisms of Drug Resistance in Chronic Myeloid Leukemia (CML)	477
53	Clinical Sensitivity to Anthracyclines in Ph/BCR+ Acute Lymphoblastic Leukemia	489
54	Differential Kinetics of Drug Resistance in Human Leukaemic Cells Measured by SCGE/CLSM	501
55	Demonstration of Differences in Drug Resistance by Direct Testing of DNA Excision Repair Activity following Standard and Liposomal Daunorubicin Exposure in Normal Pediatric Marrow Using High Resolution CLSM	509
56	Microsatellite Instability Assessment in Prediction of Drug Resistance in Childhood Burkitt's and Large Cell Diffuse Malignant Non-Hodgkin Lymphoma (MNHL)	517
57	High Resolution Confocal Laser Scanning Microscopy Analysis of DNA Excision Repair Capability in Small Volume Marrow Samples Exposed to DNA Directed Treatment Moieties	527
58	Defining the Optimal Dosage of Methotrexate for Childhood Acute Lymphoblastic Leukemia: New Insights from the Lab and Clinic	537
59	Mechanisms of Methotrexate Resistance in Acute Leukemia: Decreased Transport and Polyglutamylation	543
60	Lack of Cross-Resistance between Prednisolone and Methotrexate in Childhood Acute Lymphoblastic Leukemia? A Preliminary Analysis	551
61	New Developments in the Treatment of Acute Myeloid Leukemia	557
62	Aphidicolin Markedly Increases the in Vitro Sensitivity to Ara-C of Blast Cells from Patients with AML	567
63	Common Resistance Mechanisms to Nucleoside Analogues in Variants of the Human Erythroleukemic Line K562	571
64	Expression of DNA Mismatch Repair Proteins in Acute Lymphoblastic Leukemia and Normal Bone Marrow	579
65	Effects of CSFS and Their Combinations with Chemotherapeutic Agents (Ch) on Leukemic Blasts (LB) in Children (MTT-Assay)	585
66	Glucocorticosteroid Therapy in Childhood Acute Lymphoblastic Leukemia	593
67	Glucocorticoid Induced Apoptosis in Leukemia	607
68	Glucocorticoid Resistance and the AP-1 Transcription Factor in Leukemia	615
69	The Three Asparaginases: Comparative Pharmacology and Optimal Use in Childhood Leukemia	621
	Index	631